Home / Journals / Journal of Endocrinology, Diabetes and Metabolic Complications / Articles In Press

Mini Review

Silent Strain: Unraveling the Hidden Burden of Diabetic Cardiomyopathy

Authors: Cuskelly K11 Mizuno T11 Abagyan E11 Tamiya W11 Hallmans W11 Obarzanek F11

*Corresponding Author: Abagyan E, Department of Endocrinology, Romania

Copyright: © 2026 Abagyan E, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Abagyan E (2026). Silent Strain: Unraveling the Hidden Burden of Diabetic Cardiomyopathy V1(3)

Received: Feb 09, 2026

Accepted: Feb 18, 2026

Published: Feb 26, 2026

Keywords: asymptomatic onset, pathophysiological mechanisms, cytokine-mediated pathways, natriuretic peptides, myocardial stiffness

Abstract

Diabetic cardiomyopathy (DCM) is a distinct cardiac condition characterized by structural and functional abnormalities of the myocardium in individuals with diabetes mellitus, independent of coronary artery disease or hypertension. Often underdiagnosed due to its asymptomatic onset, DCM progresses insidiously, ultimately contributing to heart failure and increased mortality. This article explores the pathophysiological mechanisms underlying diabetic cardiomyopathy, including metabolic disturbances, oxidative stress, inflammation, and myocardial fibrosis. It also highlights clinical features, diagnostic approaches, and current management strategies, emphasizing the importance of early detection and integrated care in improving patient outcomes.

Introduction

Diabetes mellitus is a global health concern, affecting millions worldwide. While its vascular complications are well-recognized, less attention is often given to its direct effects on cardiac muscle. Diabetic cardiomyopathy represents a unique entity in which diabetes leads to myocardial dysfunction without the presence of other conventional cardiac risk factors. First described in the 1970s, DCM has gained increasing recognition as a contributor to heart failure among diabetic patients.

Pathophysiology

The development of diabetic cardiomyopathy is multifactorial, involving a complex interplay of metabolic, molecular, and structural changes:

  1. Metabolic Dysregulation:
    Chronic hyperglycemia alters cardiac energy metabolism, shifting reliance toward fatty acid oxidation. This process is less efficient and leads to the accumulation of toxic lipid intermediates in myocardial cells.

  2. Oxidative Stress:
    Elevated glucose levels increase the production of reactive oxygen species (ROS), damaging cellular components and impairing mitochondrial function.

  3. Inflammation:
    Persistent low-grade inflammation contributes to myocardial injury and remodeling through cytokine-mediated pathways.

  4. Fibrosis and Remodeling:
    Activation of fibroblasts leads to excessive collagen deposition, resulting in myocardial stiffness and impaired diastolic function.

  5. Autonomic Dysfunction:
    Diabetes can impair autonomic regulation of the heart, affecting heart rate variability and cardiac performance.

Clinical Features

Diabetic cardiomyopathy often remains asymptomatic in its early stages. As the disease progresses, patients may develop:

  • Diastolic dysfunction (early sign)

  • Reduced exercise tolerance

  • Shortness of breath

  • Fatigue

  • Eventually, symptoms of heart failure

Diagnosis

Early diagnosis is challenging but crucial. Key diagnostic tools include:

  • Echocardiography: Detects structural changes and diastolic dysfunction

  • Cardiac MRI: Provides detailed imaging of myocardial tissue

  • Biomarkers: Elevated levels of natriuretic peptides may indicate cardiac stress

  • Electrocardiography (ECG): May show nonspecific abnormalities

Importantly, diagnosis requires exclusion of other causes such as coronary artery disease and hypertension.

Management

There is no specific treatment exclusively for diabetic cardiomyopathy; management focuses on controlling diabetes and preventing cardiac progression:

  1. Glycemic Control:
    Tight blood sugar regulation helps reduce metabolic stress on the heart.

  2. Pharmacological Therapy:

    • ACE inhibitors and ARBs to reduce cardiac remodeling

    • Beta-blockers to improve cardiac function

    • SGLT2 inhibitors, which have shown cardiovascular benefits

  3. Lifestyle Modifications:

    • Regular physical activity

    • Healthy diet

    • Weight management

  4. Monitoring and Early Intervention:
    Routine cardiac screening in diabetic patients can help detect early dysfunction.

Future Perspectives

Ongoing research is exploring targeted therapies that address specific molecular pathways involved in DCM. Advances in imaging and biomarkers may allow earlier detection and more personalized treatment approaches.

Conclusion

Diabetic cardiomyopathy is a significant yet often overlooked complication of diabetes mellitus. Its silent progression underscores the need for increased awareness among clinicians and patients alike. Early detection, comprehensive management, and continued research are essential to mitigate its impact and improve cardiovascular outcomes in diabetic populations.

References

  1. Cui, M.; An, Y.; Zhao, J.; Hui, M.; Xiong, Z.; Guan, B.; Shen, Y.; Zou, Y.; Li, C.; Wang, R. Dahuang Gancao decoction suppresses ferroptosis via SIRT3-mediated NRF2 deacetylation in acute kidney injury. Phytomedicine 2026, 150, 157724.
  2. Hirschey, M.D.; Shimazu, T.; Jing, E.; Grueter, C.A.; Collins, A.M.; Aouizerat, B.; Stančáková, A.; Goetzman, E.; Lam, M.M.; Schwer, B.; et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol. Cell 2011, 44, 177–190.
  3. Dyck, J.R.B.; Sossalla, S.; Hamdani, N.; Coronel, R.; Weber, N.C.; Light, P.E.; Zuurbier, C.J. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. J. Mol. Cell. Cardiol. 2022, 167, 17–31
  4. Tan, M.; Yin, Y.; Chen, W.; Zhang, J.; Jin, Y.; Zhang, Y.; Zhang, L.; Jiang, T.; Jiang, B.; Li, H. Trimetazidine attenuates Ischemia/Reperfusion-Induced myocardial ferroptosis by modulating the Sirt3/Nrf2-GSH system and reducing Oxidative/Nitrative stress. Biochem. Pharmacol. 2024, 229, 116479.
  5. Gostner, A.; Schäffer, V.; Theis, S.; Menzel, T.; Lührs, H.; Melcher, R.; Schauber, J.; Kudlich, T.; Dusel, G.; Dorbath, D.; et al. Effects of Isomalt Consumption on Gastrointestinal and Metabolic Parameters in Healthy Volunteers. Br. J. Nutr. 2005, 94, 575–581.
  6. Scisciola, L.; Paolisso, P.; Belmonte, M.; Gallinoro, E.; Delrue, L.; Taktaz, F.; Fontanella, R.A.; Degrieck, I.; Pesapane, A.; Casselman, F.; et al. Myocardial sodium-glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: The BIO-AS study. Eur. J. Heart Fail. 2024, 26, 471–482.
  7. Corte, K.A.D.; Bosler, T.; McClure, C.; Buyken, A.E.; LeCheminant, J.D.; Schwingshackl, L.; Corte, D.D. Dietary Sugar Intake and Incident Type 2 Diabetes Risk: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies. Adv. Nutr. 2025, 16, 100413